FDA Acting Commissioner Kyle Diamantas, in his first public outline of agency priorities after the departure of controversial former commissioner Marty Makary, emphasized embracing artificial intelligence and digital tools to compete with foreign nations, improve nutrition and protect medical products from shortages.